Idiopathic Pulmonary Fibrosis
-
Lung diseases share molecular signature
Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention. Read MoreApr 5, 2018
-
Study tracks therapy to slow idiopathic pulmonary fibrosis
Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course. Read MoreFeb 1, 2018
-
Major grant enhances pulmonary fibrosis research
Vanderbilt University Medical Center (VUMC) has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF). Read MoreAug 18, 2016
-
New drugs approved to fight idiopathic pulmonary fibrosis
The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF). Read MoreJan 15, 2015
-
Lung damage protector
Targeting repair pathways in the lung’s air sacs may be a valuable therapeutic direction for pulmonary fibrosis – the scarring of lung tissue. Read MoreApr 12, 2013
-
Study examines sleep apnea’s role in lung diseases
Vanderbilt’s idiopathic pulmonary fibrosis research group is embarking on a study to determine the prevalence of sleep apnea in people with other interstitial lung diseases. Read MoreApr 13, 2012
-
Lung disorder drug regimen found harmful
Longtime treatment for IPF ineffective and even dangerous. Read MoreOct 31, 2011